Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Pramand, LLC

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Pramand, LLC

Regulatory records
4
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 4 FDA records to the applicant name Pramand, LLC. It includes 2 original PMA approvals. 2 entries are PMA supplements. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 6, 2023 to Oct 1, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code NQR appears in 4 of the 4 linked filings. The collection spans 1 FDA product code and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P220014, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 201 Burlington Rd., Suite 210, Bedford, MA, 01730. Recorded on P220014/S013, decision dated Oct 1, 2026.

Changes described in PMA records

P220014/S013: CraniSeal Dural Sealant

FDA approved a revised protocol for the CraniSeal Registry New Enrollment Post-Approval Study (PAS) for the CraniSeal Dural Sealant from Pramand, LLC. The supplement, identified as P220014/S013, was submitted to satisfy conditions of approval in the original P220014 approval order.

The decision is limited to the PAS protocol revision; it is not a new approval of the dural sealant device itself. The source statement does not describe what specific changes were made to the protocol, nor does it provide details about the study design, endpoints, or enrollment criteria. The device is categorized as a dural sealant under product code NQR.

FDA approval-order wording

Approval of the revised protocol for the CraniSeal Registry New Enrollment Post-Approval Study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P220014.

Oct 1, 2026 · Normal 180 Day Track No User Fee

P240027/S007: SpineSeal Spine Sealant

The FDA recorded approval of supplement P240027/S007 for SpineSeal™ Spine Sealant, sponsored by Pramand, LLC, on 2026-09-11. The supplement is classified as a real-time process change with the reason Change Design/Components/Specifications/Material. The recorded scope is a decrease in the lower specification limit for product swelling. This action amends the existing PMA rather than constituting a new approval of the whole sealant system.

The device falls under the dural sealant category, product code NQR, with neurology listed as the specialty. The source record does not include the prior specification value, the revised limit, supporting test data, or the supplement documents, so the magnitude and basis of the change remain unknown. No clinical or performance conclusions about the product follow from this record alone.

FDA approval-order wording

Approval to decrease the lower specification limit for product swelling.

Sep 11, 2026 · Real-Time Process

P240027: SpineSeal Spine Sealant

FDA’s recorded scope: The SpineSeal Spine Sealant is indicated for use as an adjunct to sutured dural repair during spinal surgery to provide watertight closure.

Feb 14, 2025

P220014: CraniSeal Dural Sealant

FDA approved the CraniSeal Dural Sealant from Pramand, LLC on July 6, 2023. The device is indicated for patients 18 years of age and older as an adjunct to sutured dural repair during cranial surgery to provide watertight closure.

The approval is an original PMA under product code NQR in the dural sealant category. The source statement reports the intended use but does not include clinical data, safety findings, or effectiveness endpoints. No supplement type or reason is listed, so no relationship to a prior PMA is established.

FDA approval-order wording

Approval for the CraniSeal Dural Sealant. The device is indicated for use in patients >= 18 years of age as an adjunct to sutured dural repair during cranial surgery to provide watertight closure.

Jul 6, 2023

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementOct 1, 2026FDA
Pramand, LLCPMA supplementSep 11, 2026FDA
Pramand, LLCPMA approvalFeb 14, 2025FDA
Pramand, LLCPMA approvalJul 6, 2023FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.